Recent events
Recent events tied to this brand in public sources.
Back to profile30 entries · Page 1 of 2
2026
France recalls Tavneos batches after deaths linked in Japan
France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.
2022
Lindis Biotech sues Amgen over patents
Lindis Biotech filed a complaint against Amgen in the District of Delaware, alleging that Amgen infringed three patents relating to an immunotherapy regimen. The complaint seeks a declaration of infringement and damages, among other relief; the allegations are not presented as a court determination.
2021
FDA approves Tezspire for severe asthma
The U.S. Food and Drug Administration approved Tezspire, developed by Amgen and AstraZeneca, as add-on maintenance treatment for adult and pediatric patients aged 12 years and older with severe asthma.
2021
FDA approves Kyprolis combination regimen
The U.S. Food and Drug Administration approved an expansion of Kyprolis prescribing information to include use with Darzalex Faspro and dexamethasone for certain adults with relapsed or refractory multiple myeloma.
2021
FDA approves Kyprolis combination regimen for multiple myeloma
The FDA approved a combination regimen of carfilzomib (Kyprolis), subcutaneous daratumumab and dexamethasone for adults with multiple myeloma who had received up to three previous lines of therapy.
2021
Amgen files Supreme Court petition in patent dispute
Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail required.
2021
Amgen completes acquisition of Teneobio
Amgen completed its previously announced acquisition of Teneobio in a deal worth up to $2.5 billion. The deal included Teneobio's antibody technologies and pipeline assets; three affiliates were spun off to Teneobio's current shareholders before completion.
2021
Amgen announces $900 million acquisition of Teneobio
Amgen said it will pay $900 million for Teneobio, with the deal also including future contingent milestone payments of up to an additional $1.6 billion.
2021
Amgen completes acquisition of Five Prime Therapeutics
Amgen completed its acquisition of Five Prime Therapeutics through a tender offer followed by a merger. Five Prime survived the merger, and its shares ceased trading on Nasdaq.
2021
Amgen announces three-year BioLabs LA Golden Ticket sponsorship
Amgen announced a three-year Golden Ticket sponsorship of BioLabs LA at The Lundquist Institute. The sponsorship includes an annual award for three years, with winners receiving one year of lab space and additional benefits.
2021
EVOQ Therapeutics and Amgen announce license and collaboration agreement
EVOQ Therapeutics announced a license and collaboration agreement with Amgen for discovery and development of drugs for autoimmune disorders. The companies will collaborate on preclinical development; Amgen will handle clinical development and commercialization, and will make upfront and milestone payments and pay royalties for exclusive rights to selected programs.
2020
FDA approves Amgen's RIABNI
The U.S. Food and Drug Administration approved RIABNI, an Amgen biosimilar to Rituxan, for specified adult patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.
2020
Amgen terminates collaboration with Cytokinetics
Cytokinetics said Amgen elected to terminate their collaboration, effective May 20, 2021.
2020
NewAmsterdam Pharma acquires obicetrapib rights from Amgen
NewAmsterdam Pharma acquired the rights to obicetrapib (AMG 899) from Amgen. The financial terms were not disclosed.
2020
FDA approves expanded KYPROLIS prescribing information
The U.S. Food and Drug Administration approved an expansion of KYPROLIS prescribing information to include its use with DARZALEX and dexamethasone in two dosing regimens for certain patients with relapsed or refractory multiple myeloma.
2020
FDA approves KYPROLIS combination regimen
Amgen announced that the U.S. Food and Drug Administration approved an expansion of KYPROLIS's U.S. prescribing information to include its use with DARZALEX and dexamethasone in once-weekly and twice-weekly dosing regimens for certain patients with relapsed or refractory multiple myeloma.
2020
BeiGene announces $2.08 billion equity financing
BeiGene announced a registered direct offering of 145,838,979 shares to existing investors, with gross proceeds of approximately $2.08 billion. The offering was expected to close around July 15, 2020.
2020
Amgen and Adaptive Biotechnologies collaborated on COVID-19 treatments
Amgen collaborated with Adaptive Biotechnologies to help address the COVID-19 pandemic.
2020
Amgen and Adaptive announce COVID-19 antibody development partnership
Amgen and Adaptive Biotechnologies announced a strategic collaboration to develop fully human neutralizing antibodies targeting the novel coronavirus for potential prevention or treatment of COVID-19.
2020
Amgen completes its equity investment in BeiGene
Amgen completed its purchase of approximately 20.5% of BeiGene's shares for about $2.8 billion.